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Abstract
Introduction: Massive intentional verapamil overdose is a toxic ingestion which can cause multiorgan system
failure and has no currently known antidote.
Case Presentation: The patient is a 41-year-old Caucasian woman who ingested 19.2 g of sustained release
verapamil in a suicide attempt. Our patient became hypotensive requiring three high-dose vasopressors to
maintain arterial pressure. She also developed acute respiratory failure, bradycardic ventricular rhythm necessitating
continuous transvenous pacing, and anuric renal failure. Our patient was treated with intravenous calcium,
bicarbonate, hyperinsulinemic euglycemic therapy and continuous venovenous hemodialysis without success. On
the fourth day after hospital admission continuous intravenous lipid therapy was initiated. Within three hours of
beginning lipid therapy, our patient’s vasopressor requirement decreased by half. Within 24 hours, she was on
minimal vasopressor support and regained an underlying junctional rhythm. After three days of lipid infusion, she
no longer required inotropic agents to maintain blood pressure or pacing to maintain stable hemodynamics.
Conclusions: Intravenous fat emulsion therapy may be an effective antidote for massive verapamil toxicity.
Introduction
Calcium channel blockers are commonly prescribed for
hypertension and rate control of atrial fibrillation, but
can be highly toxic in large quantities. Massive overdose
of these medications is a serious clinical problem seen
rarely in the intensive care unit; management is typically
supportive, with variable rates of success [1-4]. Here, we
report the successful use of intravenous lipid therapy to
reverse the systemic effects of severe verapamil toxicity
and we review the literature relating to this complex
problem.
Verapamil is a non-dihydropyridine calcium channel
blocker with greater cardioselectivity than diltiazem at
therapeutic levels. One review suggests that, on over-
dose, verapamil is more likely to depress atrioventricular
(AV) nodal conduction [1]. Peak plasma concentration
occurs in up to eight hours in sustained release verapa-
mil, while its half life ranges from two to eight hours
and its volume of distribution is 250 to 400 L [5]. Toxic
effects common to all calcium channel blockers include
dysrhythmias, hypotension and bradycardia from depres-
sion of the sinoatrial node. Overdose is rare but fre-
quently lethal. In a 2007 annual report of poison
centers, calcium channel blockers accounted for only
12% of all cardiovascular drug exposures but 47% of
deaths due to cardiovascular drug poisoning [6].
Reported complications include bowel infarction, stroke,
hyperglycemia, and non-cardiogenic pulmonary edema
[2]. Massive verapamil overdose, defined here as inges-
tion of greater than 8 g, is almost uniformly fatal with
few case reports of survivors [7-9].
Until recently, there has been no known antidote.
Treatment is largely supportive with gastrointestinal
decontamination and inotropic support as needed to
maintain blood pressure [2,3]. Intravenous calcium infu-
sion is logically indicated to overcome intracellular
hypocalcemia but the benefit in overdose is unclear and
may even be toxic [10]. Hyperinsulinemic euglycemia
(HIE) therapy and glucagon administration have been
suggested to improve cardiac inotropy and utilization of
glucose, with some success [2,11-13]. However, all of
these interventions act secondarily by supporting the
body while the drug is naturally eliminated, as opposed
to directly neutralizing the circulating drug. In contrast,
* Correspondence: haggda@ohsu.edu
2Department of Medicine, Oregon Health and Science University, 3181 SW
Sam Jackson Park Road, Portland, Oregon, 97201 USA
Full list of author information is available at the end of the article
Liang et al. Journal of Medical Case Reports 2011, 5:399
http://www.jmedicalcasereports.com/content/5/1/399 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Liang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.lipid infusions are thought to sequester lipophilic drugs
like verapamil thus, in theory, directly decreasing their
bioavailability in the body [14,15].
We present a case of a single-drug, massive verapamil
overdose in a failed suicide attempt that was refractory
to standard resuscitation techniques, IV calcium and
bicarbonate, HIE therapy and continuous venovenous
hemodialysis (CVVH), but rapidly responded to intrave-
nous lipid infusion.
Case Presentation
A 41-year-old Caucasian woman with a history of
depression presented to the emergency department (ED)
of a referring hospital shortly after taking 80 tablets of
sustained release verapamil 240 mg (19.2 g). At the ED,
she was treated with multiple doses of activated char-
coal, fluids and calcium, and was subsequently trans-
ferred to our intensive care unit six hours post-
ingestion. Her vital signs on admission were normal (see
Table 1 for timeline of our patient’s clinical decline and
recovery). An initial exam was unremarkable; our
patient was easily aroused, alert and oriented, and
appeared well. Serum chemistry, complete blood count
and liver function tests were normal except for a mildly
elevated serum calcium of 10.8 mg/dL and a hematocrit
of 36.5%. A urine drug screen was negative, and aceta-
minophen and salicylate levels were undetectable. Her
initial electrocardiogram (ECG) at the referring ED
showed normal sinus rhythm, left ventricular hypertro-
phy, and poor R wave progression. At the time of trans-
fer, the ECG revealed sinus bradycardia and inverted T
waves in the anterior precordial leads. Telemetry moni-
toring demonstrated occasional premature ventricular
contractions and apparent U waves. The Oregon Poison
Center was consulted at this time, and no specific anti-
dotes were initiated given the patient’s clinical appear-
ance. In particular, whole bowel irrigation was not
recommended.
Eight hours after admission, at 14 hours post-inges-
tion, our patient’s systolic blood pressure dropped to
80-90 mmHg and her heart rate to 50-60 beats per min-
ute (bpm). An ECG showed third degree AV block.
Clinically, our patient became lethargic, her oxygen
saturation dropped while on a nasal cannula and she
was placed on a 100% non-rebreather. Rapid calcium
administration, fluids and dopamine were given with no
Table 1 Timeline of the patient’s clinical course through the administration of lipids
Time Temp Pulse Rhythm BP Vent Epi Norepi Vaso
Admit
(Day 1)
36.7 59 SB 115/73 99% 2L NC 0 0 0
+8 hrs 56 Junctional 85/50 91% 6L NC 0 0 0
Abrupt clinical decline; intubation necessitated; bradycardia requiring transvenous pacer; vasopressors, furosemide, hydrocortisone, antibiotics,
calcium, insulin and glucagon infusions begun
+24 hrs
(Day 2)
38.5 100 Paced 97/60 SIMV
FiO2 80%
0.02 0.3 0.04
Hypercoagulable requiring heparin infusion; bicarbonate infusion for acidosis; oliguric with renal failure requiring continuous venovenous
hemodialysis (CVVH)
+48 hrs
(Day 3)
38.2 70 Paced 90/49 SIMV
FiO2 85%
0 0.418 0.05
Worsening respiratory status requiring airway pressure release ventilation (APRV); anuric and pacer dependent
+72 hrs
(Day 4)
38.4 70 Paced 124/72 APRV
FiO2 80%
0.04 0.75 0.05
Intravenous lipid infusion started
+76 hrs 37.5 70 Paced 149/63 APRV
FiO2 90%
0.04 0.75 0.05
+80 hrs 37.2 70 Paced 128/72 APRV
FiO2 50%
0.04 0.3 0.04
+96 hrs
(Day 5)
36.8 70 Paced 134/88 APRV
FiO2 50%
0.03 0.1 0.04
+120 hrs
(Day 6)
37.2 70 Paced 106/58 APRV
FiO2 50%
0.01 0.05 0
Improving respiratory status; APRV, CVVH, lipids, HIE, calcium, bicarbonate, and pacing stopped
+144 hrs
(Day 7)
37.6 67 Junctional 101/54 Vol A/C
FiO2 65%
0 0.03 0
Time measured as hours post-admission, which was six hours post-ingestion. Temperature recorded in Celsius. Rhythm SB: sinus bradycardia; Blood pressure (BP)
measured by cuff or arterial line if available; Vent NC: nasal cannula on liters of oxygen; SIMV: synchronized intermittent mandatory ventilation with fraction of
inspired oxygen (FiO2); APRV: airway pressure release ventilation with FiO2; Epi: epinephrine in μg/kg/min; Norepi: norepinephrine in μg/kg/min; Vaso:
vasopressin in units/min.
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heart rate. A central venous catheter was placed, and
norepinephrine and epinephrine infusions were started.
Despite these interventions, our patient’s clinical condi-
tion continued to worsen. She underwent endotracheal
intubation and a temporary transvenous pacemaker was
placed to maintain her heart rate. HIE therapy was
initiated with 10% dextrose and insulin infusions, with
the insulin initially dosed at 40 units/hr with no bolus.
Glucagon infusion was started at this time as well.
Empiric vancomycin and piperacillin/tazobactam were
added due to leukocytosis of 17,400/mm
3. Calcium
chloride infusion was continued throughout this time to
maintain an elevated ionized calcium level.
By the next morning, our patient’s blood pressure had
been stabilized with norepinephrine, epinephrine and
vasopressin infusions, and her pulse was maintained by
transvenous pacing. Insulin infusion was briefly
increased to 60 units/hr before settling at 30 units/hr.
She developed simultaneous anion and non-anion gap
metabolic acidoses and was started on a bicarbonate
infusion. Her chest X-ray and physical exam were con-
sistent with significant volume overload from her multi-
ple infusions and resuscitation, and a furosemide
infusion was started. Her central venous pressure at this
time ranged from 22 to 46 mmHg. On hospital day
three, she developed a thrombosis of her right radial
artery at the site of an arterial catheter and was started
on intravenous heparin. Her previous urine culture grew
> 100,000 colonies of Staphyloccoccus with a white
count climbing to 31,700/mm
3 and fever to 40°C; broad
spectrum antibiotics were continued. Our patient subse-
quently developed refractory hypoxemia and was
switched to airway pressure release ventilation (APRV)
with supplemental nitric oxide and cisatracurium, with
improvement in her oxygenation. She developed anuric
renal failure and was started on CVVH. As a result of
the initial resuscitation and these interventions, she
received a total of 40.7 L of fluid. Despite these thera-
pies, our patient’s condition continued to decline. At the
nadir of her clinical course, she had no underlying heart
rhythm without pacemaker support and required 0.75
μg/kg/hr of norepinephrine, 0.04 μg/kg/hr of epinephr-
ine, and 0.05 units/min of vasopressin to maintain a
perfusing mean arterial pressure.
A literature review suggested the use of lipid therapy
as a possible antidote, and on hospital day four our
patient was started on an intralipid infusion with a 100
ml bolus of 20% followed by continuous infusion at 0.5
ml/kg/hr. Three hours after the infusion was started, the
norepinephrine dose was decreased by more than 50%
to 0.3 μg/kg/hr. After a further 48 hours, vasopressin
had been stopped and her vasopressor requirement had
dropped to 0.01 μg/kg/hr of epinephrine and 0.05 μg/
kg/hr of norepinephrine. On hospital day six, our
patient regained a junctional heart rhythm with a heart
rate of 65-70 bpm and transvenous pacing was discon-
tinued. Her respiratory status had also improved signifi-
cantly enough to stop APRV, nitric oxide and
cisatracurium. On day seven, she was weaned off vaso-
pressors and changed to pressure support ventilation.
Her renal function improved, urine output increased,
and CVVH was discontinued. At this point, it was felt
that she had overcome the acute effects of verapamil
overdose, and her calcium, HIE therapy and intravenous
lipids were discontinued. Her blood pressure normalized
and her heart rhythm was sinus tachycardia with a rate
into the 110s. A total of 4,200 mL of intralipid was
administered over the initial seven days in the intensive
care unit.
Our patient’s recovery was complicated by leukocyto-
sis and tachycardia that persisted even after her blood
pressure and renal failure had improved. She had a dis-
tended abdomen, but was able to communicate and fol-
low simple commands while intubated and did not
complain of significant abdominal discomfort. A com-
puted tomography scan of her abdomen revealed pneu-
matosis intestinalis, and our patient underwent a same-
day, urgent subtotal colectomy and colostomy for
ischemic colitis. She slowly improved and was dis-
charged from the intensive care unit on 33 days after
ingesting the tablets. She was discharged from the hos-
pital on post-ingestion day 55 to a skilled nursing facil-
ity. At discharge she was alert and oriented with intact
verbal function, was able to walk with standby assis-
tance, and was eager to be discharged. At the time of
publication she has completed extensive physical rehabi-
litation and will soon be returning home to be with her
family.
Discussion
Over the past decade, intravenous fat emulsion therapy
has gained credibility as an antidote for local anesthetic
toxicity [16]. It has been a true bench-to-bedside story,
emerging from the theory of sequestering lipophilic
drugs to successful animal trials and human case reports
[17-21]. Focus is now turning to the use of lipid emul-
sions as successful antidotes for other lipophilic drugs,
such as verapamil, beta blockers, and tricyclic antide-
pressants. Most of these studies have been performed in
animal models, and case reports are now appearing to
validate the laboratory findings [16]. Despite the lack of
large trials, the anecdotal successes are compelling and
the indications and limitations for lipid therapy are now
being explored [22-24].
Several studies have demonstrated the efficacy of fat
emulsion therapy in verapamil overdose in animals
[14,15,25]. The initial study by Tebbutt et al. showed a
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time to death, the mean lethal dose and the median
lethal dose (LD50) of rodents being infused with verapa-
mil, as compared with saline [14]. Bania et al. then
demonstrated in a canine model that lipid infusion com-
bined with standard resuscitation techniques led to
increased survival, characterized by increased mean
arterial pressures detectable within 30 minutes of start-
ing the lipid infusion. At 60 minutes, there was a signifi-
cant improvement in maximal ventricular pressure, and
an observed but non-significant improvement in heart
rate, cardiac output, and systemic vascular resistance. At
120 minutes, the survival percentage of animals receiv-
ing lipid therapy was 100%, compared to 14% survival of
controls receiving saline [25]. A follow-up study in
rodents showed that the greatest survival benefit with
bolus dosing occurred at 18.6 ml/kg, while the greatest
benefit to heart rate, mean arterial pressure, and base
excess occurred at 24.8 ml/kg. These doses are higher
than the recommended maximal daily dose of 10 ml/kg/
day used for artificial parenteral nutrition in humans,
which suggests that high dosing may be necessary to
reverse severe drug toxicity [15].
Three recent cases illustrate the potential of lipid ther-
apy in calcium channel blocker overdose. Young et al. pre-
sent a case of multidrug overdose including 13.44 g of
verapamil in combination with bupropion, zolpidem, que-
tiapine, clonazepam and benazepril [26]. Their patient pre-
sented to the hospital hypotensive and acidotic, requiring
mechanical ventilation and norepinephrine to maintain
arterial pressure. Lipid therapy was initiated almost imme-
diately upon arrival, and within an hour the norepinephr-
ine dose was halved. The patient was extubated on day
two, and discharged on day five with no neurologic defi-
cits. Montiel et al. describe a second case of a patient who
ingested 3.6 g of sustained-release diltiazem who was trea-
ted with hyperinsulinemic euglycemia therapy in combina-
tion with lipid therapy [27]. Their patient had an
improvement in blood pressure within one hour of begin-
ning intravenous lipid, and was discharged from the inten-
sive care unit on day nine with a full recovery. Finally,
French et al. report a case of sustained verapamil overdose
treated with lipid emulsion therapy. Notably, the serum
level of verapamil in their case was slightly decreased after
administration of lipids [28].
This is the second report of intralipid fat emulsion
therapy being used in verapamil overdose, both in con-
junction with high dose insulin and having a benefit
after HIE has failed. Significantly, intralipid fat emulsion
therapy was given for a longer period than in prior
reports, and in response to a much larger overdose of
verapamil. Our case demonstrates that lipid therapy can
be effective in a pure, massive overdose of sustained-
release verapamil, and that this efficacy can manifest
several days after ingestion. Our patient was initially
managed conservatively with standard resuscitation
techniques and care was escalated as her clinical condi-
tion declined; lipid therapy was started as it became
clear that she was worsening despite our best treatment.
Although a causal relationship between lipid therapy
and clinical improvement cannot be definitively deter-
mined, the time course of her recovery is compelling.
Within hours of starting the lipid therapy, her disease
course abruptly reversed, and within days she had
regained an intrinsic heart rhythm and no longer
required pacing or vasopressors. In retrospect, her need
for additional therapies, including transvenous pacing,
high-dose vasopressors and/or inotropes, HIE therapy,
bicarbonate infusion, broad spectrum antibiotics and
continuous hemodialysis, may have been lessened if
lipid therapy had been started earlier.
The optimal dose, timing, and duration of therapy
remain unclear. Animal studies of lipid infusion with
verapamil toxicity have used primarily single bolus dos-
ing, while case reports commonly include an initial
bolus plus continuous infusion. Our initial dosing was
based on previous case reports [26], and the duration of
therapy was determined by our patient’sc l i n i c a l
improvement. In general, however, intravenous fat emul-
sions have been given safely and routinely to critically ill
patients as parenteral nutrition. Adverse effects in the
acute period include allergic reaction and the potential
to develop fat or pulmonary emboli. Patients requiring
long-term use may also develop liver dysfunction.
Conclusion
Intravenous lipid therapy is a plausible and effective
therapy for massive calcium channel blocker overdose,
and could be considered early in patients presenting
with hemodynamic compromise.
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